{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:42:33Z","timestamp":1785796953508,"version":"3.56.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.rmed.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T13:15:28Z","timestamp":1465305328000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis"],"prefix":"10.1016","volume":"117","author":[{"given":"Robert","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Aksamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Goeminne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.rmed.2016.06.007_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society Bronchiectasis (non-CF) Guideline Group","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/qjmed\/hct109","article-title":"Non-cystic fibrosis bronchiectasis","volume":"106","author":"McDonnell","year":"2013","journal-title":"Q.\u00a0J. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non-cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib4","doi-asserted-by":"crossref","first-page":"e71109","DOI":"10.1371\/journal.pone.0071109","article-title":"Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends","volume":"8","author":"Ringhausen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2016.06.007_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","article-title":"Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis","volume":"108","author":"Goeminne","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respir. Med."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2016.06.007_bib7","doi-asserted-by":"crossref","first-page":"A138","DOI":"10.1136\/thoraxjnl-2012-202678.233","article-title":"Time trends in incidence and prevalence of bronchiectasis in the UK","volume":"67","author":"Quint","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007","volume":"142","author":"Seitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2016.06.007_bib9","series-title":"The European Lung White Book: Respiratory Health and Disease in Europe","first-page":"176","article-title":"Bronchiectasis","year":"2013"},{"key":"10.1016\/j.rmed.2016.06.007_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.08-0776","volume":"134","author":"O\u2019Donnell","year":"2008","journal-title":"Bronchiectasis. Chest"},{"key":"10.1016\/j.rmed.2016.06.007_bib11","first-page":"6","article-title":"Inflammation: a two-edged sword\u2014the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"key":"10.1016\/j.rmed.2016.06.007_bib12","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S2213-2600(13)70005-5","article-title":"Bronchiectasis: breaking the cycle of inflammation and infection","volume":"1","author":"Mandal","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"Tunney","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1183\/09031936.00052712","article-title":"A\u00a0molecular comparison of microbial communities in bronchiectasis and cystic fibrosis","volume":"41","author":"Duff","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1513\/AnnalsATS.201310-335OC","article-title":"A\u00a0novel microbiota stratification system predicts future exacerbations in bronchiectasis","volume":"11","author":"Rogers","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2016.06.007_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1465-9921-13-21","article-title":"Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients","volume":"13","author":"Goeminne","year":"2012","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2016.06.007_bib18","doi-asserted-by":"crossref","first-page":"e113373","DOI":"10.1371\/journal.pone.0113373","article-title":"Characterization of lung function impairment in adults with bronchiectasis","volume":"9","author":"Guan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2016.06.007_bib19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2016.06.007_bib20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.rmed.2014.07.021","article-title":"Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance","volume":"109","author":"McDonnell","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2012-203105","article-title":"Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition","volume":"68","author":"Rogers","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib22","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","article-title":"Effect of sputum bacteriology on the quality of life of patients with bronchiectasis","volume":"10","author":"Wilson","year":"1997","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score","volume":"43","author":"Martinez-Garcia","year":"2014","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/thoraxjnl-2013-203739","article-title":"National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care?","volume":"69","author":"Hill","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1157\/13128330","article-title":"Diagnosis and treatment of bronchiectasis. Spanish society of pneumology and thoracic surgery","volume":"44","author":"Vendrell","year":"2008","journal-title":"Arch. Bronconeumol"},{"key":"10.1016\/j.rmed.2016.06.007_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000438490","article-title":"Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"90","author":"Orriols","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2016.06.007_bib29","unstructured":"European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC). European Respiratory Society announces Bronchiectasis Guidelines Task Force. https:\/\/www.bronchiectasis.eu\/Contents\/Item\/Display\/237. Date last updated: 2014. Date last accessed: December 30, 2014."},{"key":"10.1016\/j.rmed.2016.06.007_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thoraxjnl-2015-206956","article-title":"Reclaiming the name \u2019bronchiectasis\u2019","volume":"70","author":"Chalmers","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib31","first-page":"67","article-title":"Non-cystic fibrosis bronchiectasis: review and recent advances","volume":"1","author":"Livnat","year":"2009","journal-title":"F100 Med. Rep."},{"key":"10.1016\/j.rmed.2016.06.007_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.prrv.2010.05.003","article-title":"Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"11","author":"Stuart","year":"2010","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.rmed.2016.06.007_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2016.06.007_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcf.2011.01.002","article-title":"Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs 2009","volume":"10","author":"Lillquist","year":"2011","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.rmed.2016.06.007_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"For the EPIC Investigators. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2016.06.007_bib37","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","article-title":"European cystic fibrosis society standards of care: best practice guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.rmed.2016.06.007_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"D\u00f6ring","year":"2004","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.rmed.2016.06.007_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rmed.2011.11.018","article-title":"Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis","volume":"106","author":"White","year":"2012","journal-title":"Resp. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib40","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"11","author":"Langton Hewer","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2016.06.007_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccm.2012.03.001","article-title":"Evaluating success of therapy for bronchiectasis: what end points to use?","volume":"33","author":"Smith","year":"2012","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1164\/ajrccm.156.2.9607083","article-title":"Validation of the St. George\u2019s respiratory questionnaire in bronchiectasis","volume":"156","author":"Wilson","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1164\/rccm.201404-0638ED","article-title":"Nebulized colistin for non-cystic fibrosis bronchiectasis: d\u00e9j\u00e0 vu all over again?","volume":"189","author":"Metersky","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib44","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2016.06.007_bib45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2180-14-130","article-title":"Polymicrobial airway bacterial communities in adult bronchiectasis patients","volume":"14","author":"Purcell","year":"2014","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.rmed.2016.06.007_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/thoraxjnl-2014-205826","article-title":"Respiratory microbiota: addressing clinical questions, informing clinical practice","volume":"70","author":"Rogers","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2016.06.007_bib47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(14)61136-3","article-title":"The role of the microbiome in exacerbations of chronic lung diseases","volume":"384","author":"Dickson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2016.06.007_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib49","unstructured":"US National Institutes of Health Clinical Trial, Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 1), Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764841. Last accessed 10\/5\/16."},{"key":"10.1016\/j.rmed.2016.06.007_bib50","unstructured":"US National Institutes of Health Clinical Trial, Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 2), Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02106832. Last accessed 10\/5\/16."},{"key":"10.1016\/j.rmed.2016.06.007_bib51","unstructured":"US National Institutes of Health Clinical Trial, Phase 3 Study with Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis (ORBIT-3), Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01515007. Last accessed 10\/5\/16."},{"key":"10.1016\/j.rmed.2016.06.007_bib52","unstructured":"US National Institutes of Health Clinical Trial, Phase 3 Study with Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis (ORBIT-4), Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02104245. Last accessed 10\/5\/16."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.rmed.2016.06.007_bib53","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(11)60011-8","article-title":"Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report","volume":"10","author":"Pressler","year":"2011","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.rmed.2016.06.007_bib54","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2016.06.007_bib55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2016.06.007_bib56","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. The BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2016.06.007_bib57","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.rmed.2014.09.005","article-title":"Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions","volume":"108","author":"Haworth","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.2013.2780","article-title":"Macrolides and bronchiectasis: clinical benefit with a resistance price","volume":"309","author":"Elborn","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2016.06.007_bib59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5114\/aoms.2014.44857","article-title":"Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis","volume":"10","author":"Chu","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.rmed.2016.06.007_bib60","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1016\/j.ijid.2013.03.018","article-title":"Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis","volume":"17","author":"Mirsaeidi","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.rmed.2016.06.007_bib61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2466-14-124","article-title":"Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery: the importance of histological assessment of specimens: a cohort study","volume":"14","author":"Char","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.rmed.2013.09.014","article-title":"Nontuberculous mycobacterial (NTM) lung diseases: the top ten essentials","volume":"108","author":"Aksamit","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.rmed.2016.06.007_bib64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.rmed.2016.06.007_bib65","first-page":"A3192","article-title":"Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and non-cystic fibrosis bronchiectasis patients","volume":"181","author":"Bruinenberg","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.06.007_bib66","unstructured":"CIPRO Summary of Product Characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/20346\/SPC\/Ciproxin+Tablets+500mg\/. Last accessed 28\/4\/16."},{"issue":"3","key":"10.1016\/j.rmed.2016.06.007_bib67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"Suppl.\u00a054","key":"10.1016\/j.rmed.2016.06.007_bib68","first-page":"5574","article-title":"Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis","volume":"36","author":"Bruinenberg","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.06.007_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1378\/chest.13-1891","article-title":"A\u00a0preliminary quality of life questionnaire-bronchiecasis: a patient-reported outcome measure for bronchiectasis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2016.06.007_bib70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116301317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116301317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:37:01Z","timestamp":1760614621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611116301317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":70,"alternative-id":["S0954611116301317"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2016.06.007","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}